Can a new drug help myasthenia gravis patients ditch steroids?
NCT ID NCT07221838
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether the drug ravulizumab can help people with generalized myasthenia gravis (gMG) safely reduce or stop taking oral steroids. About 75 adults who are already on ravulizumab and taking at least 7.5 mg of prednisone daily will follow a gradual steroid-tapering schedule. The goal is to see if they can lower their steroid dose to 5 mg or less per day—or stop entirely—without their muscle weakness getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ravulizumab (intravenous) and prednisone/prednisolone (oral corticosteroid)
What this could lead to
If successful, this study could show that ravulizumab allows many patients with generalized myasthenia gravis to safely reduce or stop long-term steroid use, lowering side effects.
What could go wrong
This is a small, single-arm study (no placebo group), so results may not prove cause and effect. Steroid tapering may not work for everyone, and some patients might experience symptom worsening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGChicago, Illinois, 60637, United States
-
Research Site
NOT_YET_RECRUITINGSchaumburg, Illinois, 60173, United States
-
Research Site
NOT_YET_RECRUITINGNeptune City, New Jersey, 07753, United States
-
Research Site
RECRUITINGRaleigh, North Carolina, 27607, United States
-
Research Site
NOT_YET_RECRUITINGKnoxville, Tennessee, 37920, United States
-
Research Site
NOT_YET_RECRUITINGBochum, 44789, Germany
-
Research Site
NOT_YET_RECRUITINGMilan, 20122, Italy
-
Research Site
NOT_YET_RECRUITINGNaples, 80131, Italy
-
Research Site
NOT_YET_RECRUITINGRome, 00189, Italy
-
Research Site
NOT_YET_RECRUITINGIbaraki, 305-8576, Japan
-
Research Site
NOT_YET_RECRUITINGKitakyushu-shi, 807-8555, Japan
-
Research Site
NOT_YET_RECRUITINGKumamoto, 860-8556, Japan